Immuneering (IMRX) Depreciation & Amortization (CF) (2020 - 2026)
Immuneering (IMRX) recorded quarterly Depreciation & Amortization (CF) of $81402.0 in Q1 2026, up 7.26% quarter-over-quarter from $75889.0 in Q4 2025, and down 4.53% on a YoY basis from $85261.0 in Q1 2025.
Immuneering (IMRX) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Immuneering's Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $81402.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 4.53% year-over-year to $81402.0; the TTM figure through Mar 2026 stood at $320659.0 (down 8.61% YoY), while the FY2025 annual figure was $324517.0, down 8.79% from the prior year.
- Depreciation & Amortization (CF) was $81402.0 for Q1 2026 at Immuneering, up from $75889.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $90533.0 in Q2 2024 to a low of $47704.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $78337.9 across 5 years, with a median of $78841.0 in 2025.
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) surged 468.33% in 2022, then retreated 11.88% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $76862.0 in 2022, then climbed by 16.77% to $89754.0 in 2023, then decreased by 4.05% to $86116.0 in 2024, then declined by 11.88% to $75889.0 in 2025, then advanced by 7.26% to $81402.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $81402.0 (Q1 2026), $75889.0 (Q4 2025), and $78841.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 429,663.65 |
| 10 | Immuneering | 255.40 Mn | 255.40 Mn | - | 81,402.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 81,402.00 |
| Mar 31, 2026 | 81,402.00 |
| Dec 31, 2025 | 75,889.00 |
| Dec 31, 2025 | 75,889.00 |
| Sep 30, 2025 | 78,841.00 |
| Sep 30, 2025 | 78,841.00 |
| Jun 30, 2025 | 84,527.00 |
| Jun 30, 2025 | 84,527.00 |
| Mar 31, 2025 | 85,261.00 |
| Mar 31, 2025 | 85,261.00 |
| Dec 31, 2024 | 86,116.00 |
| Dec 31, 2024 | 86,116.00 |
| Sep 30, 2024 | 88,949.00 |
| Sep 30, 2024 | 88,949.00 |
| Jun 30, 2024 | 90,533.00 |
| Jun 30, 2024 | 90,533.00 |
| Mar 31, 2024 | 90,209.00 |
| Mar 31, 2024 | 90,209.00 |
| Dec 31, 2023 | 89,754.00 |
| Dec 31, 2023 | 89,754.00 |